TriangleNCT00303719 · STUDY IN CONTEXT
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Successful sustained engraftment is defined as primary neutrophil engraftment by day 42 and e90% donor cells at day 100, with or without DLI. Engraftment based on absolute neutrophil count of donor origin \> 0.5 x 10e9 /L for 3 days by day 42
Safety by development of severe adverse events within 100 days of transplant
\> 30% transplant related mortality at 100 days (non-relapse).
Overall Survival
Grade III-IV graft versus host disease
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- trial label
- Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 5
- harms Count
- 2
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0000
- source section id
- NCT00303719-om-0000
- source outcome index
- 0
- endpoint
- Neutrophil and Donor Cell Engraftment
- endpoint definition
- Successful sustained engraftment is defined as primary neutrophil engraftment by day 42 and e90% donor cells at day 100, with or without DLI. Engraftment based on absolute neutrophil count of donor origin \> 0.5 x 10e9 /L for 3 days by day 42
- time origin
- Day 42 and Day 100
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0001
- source section id
- NCT00303719-om-0001
- source outcome index
- 1
- endpoint
- Serious Adverse Events
- endpoint definition
- Safety by development of severe adverse events within 100 days of transplant
- time origin
- Day 100
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0002
- source section id
- NCT00303719-om-0002
- source outcome index
- 2
- endpoint
- Transplant Related Mortality
- endpoint definition
- \> 30% transplant related mortality at 100 days (non-relapse).
- time origin
- Day 100
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0003
- source section id
- NCT00303719-om-0003
- source outcome index
- 3
- endpoint
- Overall Survival
- endpoint definition
- Overall Survival
- time origin
- 1 year
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0004
- source section id
- NCT00303719-om-0004
- source outcome index
- 4
- endpoint
- Acute Graft-Versus-Host Disease
- endpoint definition
- Grade III-IV graft versus host disease
- time origin
- Day 100
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0000
- arm key
- OG000
- arm label
- High Risk Patients
- regimen
- Patients with refractory leukemia or MDS
- analyzed count
- 13
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0000
- arm key
- OG001
- arm label
- Standard Risk Patients
- regimen
- Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome, Renal cell cancer,Chronic myeloproliferative disorder
- analyzed count
- 292
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0000#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0001
- arm key
- OG000
- arm label
- High Risk Patients
- regimen
- Patients with refractory leukemia or MDS
- analyzed count
- 13
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0001
- arm key
- OG001
- arm label
- Standard Risk Patients
- regimen
- Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome, Renal cell cancer,Chronic myeloproliferative disorder
- analyzed count
- 292
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0001#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0002
- arm key
- OG000
- arm label
- High Risk Patients
- regimen
- Patients with refractory leukemia or MDS
- analyzed count
- 13
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0002
- arm key
- OG001
- arm label
- Standard Risk Patients
- regimen
- Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome,Chronic myeloproliferative disorder
- analyzed count
- 292
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0002#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0003
- arm key
- OG000
- arm label
- High Risk Patients
- regimen
- Patients with refractory leukemia or MDS
- analyzed count
- 13
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0003
- arm key
- OG001
- arm label
- Standard Risk Patients
- regimen
- Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome,Chronic myeloproliferative disorder
- analyzed count
- 292
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0003#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0004
- arm key
- OG000
- arm label
- High Risk Patients
- regimen
- Patients with refractory leukemia or MDS
- analyzed count
- 13
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0004#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- outcome key
- om-0004
- arm key
- OG001
- arm label
- Standard Risk Patients
- regimen
- Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome, Renal cell cancer,Chronic myeloproliferative disorder
- analyzed count
- 292
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00303719-om-0004#groups/OG001
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- harm key
- EG000
- source section id
- NCT00303719-ae
- event group key
- EG000
- event group label
- High Risk Patients
- serious affected
- 1
- serious at risk
- 13
- other affected
- 12
- other at risk
- 13
- frequency threshold
- 5
- collection period
- 2 years
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-plasma-cell-neoplasms
- nct id
- NCT00303719
- harm key
- EG001
- source section id
- NCT00303719-ae
- event group key
- EG001
- event group label
- Standard Risk Patients
- serious affected
- 53
- serious at risk
- 292
- other affected
- 272
- other at risk
- 292
- frequency threshold
- 5
- collection period
- 2 years
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice